abexinostat

September 26, 2019

FDA Grants Abexinostat Fast Track Status for Follicular Lymphoma

News

Xynomic Pharmaceutical‘s abexinostat has received Fast Track Designation by the U.S. Food and Drug Administration (FDA) as a fourth-line treatment for follicular lymphoma, the company announced in a press release. ... Read more

August 20, 2019

Clinical Trials in China Will Test Abexinostat for DLBCL, Follicular Lymphoma

News

Xynomic Pharma is launching two pivotal clinical trials in China to test its investigational HDAC inhibitor, abexinostat, as a third-line therapy for two types of non-Hodgkin’s lymphoma: diffuse large B-cell lymphoma (DLBCL) and follicular ... Read more

August 8, 2019September 10, 2019

FDA Asked to Place Abexinostat, Possible Follicular Lymphoma Treatment, on Fast Track

News

Xynomic Pharmaceuticals has filed a request with U.S. Food and Drug Administration (FDA) asking that abexinostat, its lead therapeutic candidate for relapsed or refractory follicular lymphoma, be given fast track designation. The ... Read more

August 2, 2019August 2, 2019

First Patient Dosed in Trial Testing Abexinostat-Imbruvica Combo for Advanced Lymphomas

News

Xynomic Pharma has initiated patient dosing in a Phase 1/2 trial testing its investigational therapy abexinostat, in combination with Imbruvica (ibrutinib), as a treatment for people with mantle cell lymphoma (MCL) and ... Read more

March 26, 2019

Trials to Test Abexinostat in Heavily Treated DLBCL, Follicular Lymphoma

News

Xynomic Pharma is preparing two new Phase 2 trials in China to explore the activity of its investigational HDAC inhibitor, abexinostat, as third-line therapy for diffuse large B-cell lymphoma (DLBCL) ... Read more

June 12, 2018

Xynomic Pharma Plans 4 Clinical Trials of Abexinostat for Lymphoma

News

Xynomic Pharma announced it has completed a new Series B financing round and now will initiate eight clinical trials, four of which are for different types of lymphoma, in the next 12 ... Read more

February 1, 2017

Abexinostat Shows Potential as Lymphoma Treatment in European Clinical Trial

News

A clinical trial of the investigational drug abexinostat in patients with non-Hodgkin’s lymphoma or chronic lymphocytic leukemia demonstrated that the treatment may be suitable for these types of cancer, but ... Read more